INTRODUCTION
Raynaud's phenomenon occurs in almost all patients with systemic sclerosis (SSc) [1] and can be very severe, often progressing to digital ulceration (in around 50% of patients) ( Fig. 1 ) and occasionally to gangrene [2,3 && ]. This severity relates to the fact that in SSc, structural as well as functional vascular abnormalities occur, in contrast to primary (idiopathic) Raynaud's phenomenon when the vascular abnormality is thought to be purely functional and entirely reversible, never progressing to irreversible tissue injury. Recent studies have highlighted the burden of associated disability of both Raynaud's phenomenon (1) What mechanisms drive the digital vasculopathy and lead to structural as well as functional change? (2) Can we predict which patients progress to digital ulceration? (3) Can we measure disease process reliably (in terms of both Raynaud's phenomenon and
PATHOPHYSIOLOGY

Raynaud's phenomenon
The pathophysiology of Raynaud's phenomenon is complex and most likely involves an interplay between vascular factors, neural control mechanisms and intravascular factors [6] . Flavahan [7 && ], in a recent review, describes thermoregulatory mechanisms as central to an understanding of Raynaud's phenomenon, highlighting the role of arteriovenous anastomoses, and how local cooling leads to increased activity of alpha 2 -adrenoceptors, resulting in reduced blood flow. In patients with SSc, structural microvascular changes mean that upstream vasoconstriction can irretrievably compromise nutritional blood flow and lead to tissue injury [7 && ,8] . The review also gives a framework for targeted therapeutic interventions [7 && ].
Digital ulceration
A commonly held view is that fingertip ulceration is ischaemic, whereas ulceration over the extensor surfaces of fingers is 'traumatic'. To date there has been very little direct evidence to support this theory. However, a study by Ruaro et al. 
KEY POINTS
Digital vasculopathy is one of the major contributors to pain and disability in patients with SSc.
Pathophysiology remains elusive, but more is now known about the mechanisms of thermoregulatory imbalance and of structural vasculopathy.
Research is ongoing into outcome measures, including into definition of digital ulcers.
Randomised controlled trials, both early phase and larger multicentre, are feasible and providing an evidence base to treatment (e.g. for PDE5 inhibitors).
Other treatment approaches (e.g. botulinum toxin injections) are being advocated, but controlled clinical trials and/or carefully designed observational studies are required. ] summarised reported correlations between a large number of 'vascular biomarkers' and digital ulcers, and also with nailfold capillaroscopic change. Although associations do not prove causation, nonetheless it is tempting to speculate that some of the associates of digital ulceration might in the future be targets for therapy. 
PREDICTORS OF DIGITAL ULCERATION
MEASUREMENT OF DISEASE PROCESS
Raynaud's phenomenon
The only validated measure of Raynaud's phenomenon is the Raynaud's Condition Score [26] . Clinical trials tend to rely on this and other patient reported outcomes, namely frequency, duration and severity of attacks. However, patient reported outcome measures are subjective, and a vision is to develop objective, noninvasive measures of digital blood flow: although these are unlikely to be used in large multicentre studies they have potential in proof-ofconcept, early phase studies. Methods currently being used include thermography (an indirect measure of blood flow) and laser Doppler techniques [27,28,29
However, full validation and standardisation of protocols is required before these can be used more widely.
Digital ulceration
Digital ulcers are often a primary endpoint in randomised controlled trials (RCTs), and yet there is poor agreement as to their definition [31, 32] . A recent study [33 & ] showed that adding contextual information (e.g. presence of pain, discharge) to the visible appearance of the ulcers did not improve reliability. International efforts to standardise definition are ongoing.
TREATMENT
The purpose of this article is not to provide a stateof-the-art review of management but rather to highlight key recent advances. The UK Scleroderma Study Group consensus best practice pathways [34 & ] provides flow-charts of current management of Raynaud's phenomenon, digital ulceration and critical ischaemia, but with the proviso (as discussed below) that these pathways are already slightly outdated because phosphodiesterase type 5 (PDE5) inhibitors should now be 'moved up' the pathways. Clinical practice will vary between countries depending on accessibility to the different treatments. Other than bosentan, the drugs discussed are not licensed for SSc-related digital vasculopathy.
Raynaud's phenomenon (which has not progressed to digital ulceration or critical ischaemia)
A recent systematic review highlighted the lack of evidence base for treatment of SSc-related Raynaud's phenomenon [35] . However, progress is being made. The major point to highlight in the last 18 months for the practising clinician has been the increased use of PDE5 inhibitors, and many clinicians are now very likely to use a PDE5 inhibitor as a second choice after a calcium channel blocker in patients with SSc-related Raynaud's phenomenon. This is because first, PDE5 inhibitors have now been shown to confer benefit in a number of RCTs [36] [37] [38] [39] , and in a recent metaanalysis [40] (although the trials were all short-term, with a treatment period of 6 weeks or less) and second, reduced costs of PDE5 inhibition from previously. Fig. 2 ]. It will be interesting to see how the situation changes over the next 2 to 3 years. ]. Phosphodiesterase inhibition has been 'moved up' the original pathway to be positioned along with other oral vasodilator therapies. Note that clinicians outside the UK might modify their approach depending on their access to therapies. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blockers; PDE5, phosphodiesterase type 5; SSRI, selective serotonin reuptake inhibitor.
As Fig. 2 outlines, intravenous prostanoids are used in some cases of severe 'uncomplicated' Raynaud's phenomenon (Raynaud's phenomenon which has not progressed to digital ulceration or critical ischaemia), but require hospitalisation. Selexipag, an oral IP prostacyclin receptor agonist which has been shown to be effective in pulmonary arterial hypertension, held promise also for Raynaud's phenomenon. Disappointingly, a recent clinical trial, so far published only in abstract form [42] , showed no benefit from selexipag in SScrelated Raynaud's phenomenon.
It seems likely that in SSc-related digital vasculopathy as in pulmonary arterial hypertension, combination therapy may be helpful given that different classes of drugs have very differing (and potentially synergistic) modes of action. Bellando-Randone et al. [43] reported a retrospective study of 123 patients with SSc and suggested that combination treatment with bosentan and sildenafil conferred benefit on Raynaud's phenomenon. Prospective studies are required.
RCTs of Raynaud's phenomenon are, however, challenging, given the heterogeneity of Raynaud's phenomenon, the requirement to run studies over the winter months, and the subjectivity of patient reported outcome measures. Early phase proof-ofconcept studies allow early assessment of promising therapies. Bose et al. [44 & ] reported a 12-week double-blind, parallel-group, controlled trial comparing the endothelin Type A receptor antagonist ambrisentan (15 patients) with placebo (5 patients). Although no improvement in finger blood flow was demonstrated with ambrisentan (as assessed by laser Doppler perfusion imaging), as the authors concluded, there are a number of different mechanisms through which ET-1 blockade could exert benefit in SSc-related digital vasculopathy and ET-1 receptor antagonists warrant further research. Fig. 3 providing a summary flow-chart of current practice. Recent studies have highlighted the importance of adequate analgesia [48, 49] : this is welcome as this key aspect of care is sometimes overlooked. 
Digital ulcers
Several recent reviews give detailed descriptions of management [45 & -47 & ], with
Randomised controlled trials
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8. [50 && ]. Although the primary end-point (time to healing) was not reached, sildenafil conferred some benefit with a greater healing rate in the sildenafil group compared with placebo at week 8 (P ¼ 0.01) and week 12 (P ¼ 0.03). The DUAL-1 and DUAL-2 studies [51 && ], randomising 289 and 265 patients, respectively, both compared (over 16 weeks) macitentan 3 mg daily, macitentan 10 mg daily and placebo (1 : 1 : 1 randomisation). Macitentan, similarly to bosentan (which is licensed for the prevention of SSc-related digital ulcers) is a dual ETreceptor antagonist but has sustained receptor binding and increased tissue penetration. It reduces morbidity and mortality in pulmonary arterial hypertension [52] and was therefore a promising treatment for SSc-related digital ulcers. However, the cumulative number of new ulcers (the primary endpoint for each of DUAL-1 and DUAL-2) was no different between macitentan and placebo treatment: DUAL-2 was halted prematurely on the recommendation of the independent data monitoring committee. Irrespective of their outcomes, the SEDUCE and DUAL studies are testimony to the ability of the international community to mount large-scale multicentre studies of SSc-digital ulcers. This represents a major step forward, and will facilitate addressing the need (highlighted by a metaanalysis in 2013 [53] ) for larger studies with standardised outcome measures.
Observational studies of vasoactive therapies
The RAPIDS-1 and RAPIDS-2 RCTs studies demonstrated the efficacy of bosentan in the prevention of SSc-related digital ulceration [54, 55] . Agard et al. [56 & ] conducted a retrospective study in 10 French centres to examine characteristics of 89 patients treated with bosentan in a 'real-world' setting: patients treated with bosentan (median treatment duration until data collection was 17.5 months) had severe disease (61% with at least two previous digital ulcer episodes, and 63% had had previous intravenous iloprost infusions). As with 'uncomplicated' Raynaud's phenomenon, there is increasing interest in combination therapy: a retrospective analysis of 34 patients suggested that adding bosentan to monthly iloprost infusions was associated with ulcer healing in around 50% of patients [57] . Although ideally controlled trials of combination therapy are needed, study design will prove highly challenging.
Procedural treatments
In SSc, these tend to be confined to patients who have progressed to digital ulceration or critical ischaemia. The increasing interest in botulinum toxin injections continues [58] , with a prospective study of 20 patients with SSc reporting improvement in hand function after 8 weeks [59] . RCTs are required and are underway.
Digital sympathectomy [60, 61] also continues to attract interest and is probably being performed increasingly in specialist centres. A recent retrospective study of 17 patients with SSc (26 hands operated on) reported symptomatic improvement in pain in 92.3% of hands and ulcer healing in all patients [62 & ], with the authors suggesting that the procedure should be considered earlier on in the disease rather than as a 'last resort'.
Fat grafting has been proposed as another possible therapy for severe secondary Raynaud's phenomenon [63] . Extracorporeal shock wave therapy was reported to confer some benefit in a study of 9 patients with SSc and 49 ulcers [64] .
Therefore more 'aggressive' approaches to digital ulceration are being investigated and gaining ground. Although a systematic review concluded that the evidence base for surgical procedures for Raynaud's phenomenon is lacking [65 & ], this is perhaps unsurprising given the relatively small numbers of patients coming to surgery and the difficulties in mounting clinical trials. Observational studies with standardised outcome measures should be encouraged.
Topical therapies
Many patients with Raynaud's phenomenon, with or without digital ulcers, do not tolerate oral or intravenous treatment because of systemic vasodilatory side effects. Effective topical therapies which act locally on the digits, and which are free from systemic side effects, are badly needed. It is encouraging that both preclinical and human studies are exploring topical delivery systems, including with iontophoresis, to improve blood flow [66] [67] [68] . An exciting potential development is the prospect of being able to apply local therapies to ulcers to induce angiogenesis and promote healing: a study in UCD-206 chickens showed that application of VEGF 121 -fibrin in a gel matrix improved ischaemic comb and neck lesions, with increased microvascular density compared with in fibrin treated and untreated lesions [69 && ].
CONCLUSION
Advances in the understanding and treatment of SSc-related digital vasculopathy have been published in the last 12-18 months. Patients at high risk of progressing to digital ulcers can now be better identified, paving the way for studies of early intervention. Large multicentre studies can and are being mounted, and also smaller proof of concept studies of novel treatment modalities (facilited by standardisation of outcome measures). The next 5 years should see further translation of research findings into patient benefit.
Acknowledgements
None.
Financial support and sponsorship None.
Conflicts of interest A.L.H. has done consultancy work for Actelion, served on a Data Safety Monitoring Board for Apricus, received research funding and speaker's fees from Actelion, and speaker's fees from GSK. She is or has recently been a principal investigator on studies sponsored by Actelion and Bayer. This study of 110 patients with a very early diagnosis of SSc (VEDOSS) included 25 with digital ulcers, all of whom had pulmonary and/or gastro-intestinal involvement of their disease: the conclusion was that digital ulcers were a 'sentinel sign' for internal organ involvement. 25. A highlight of this review is three case histories which gives the reader a practical approach to management of different severities of SSc-related digital vasulopathy. 47.
REFERENCES AND RECOMMENDED READING
